LMRI (Lumexa Imaging Holdings, Inc. Common Stock)
Insider Trading Activity
Every open-market purchase and sale reported by LMRI officers, directors and 10%+ beneficial owners on SEC Form 4, which must be filed within two business days of the transaction. Sales often reflect scheduled 10b5-1 plans or tax withholding rather than a directional view, so read counts alongside the size and the filer.
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.
| Filed | Insider | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| 2026-06-12 | Bridget E Karlin | Director | A | — | — |
| 2026-06-12 | BRETT BRODNAX | Director | A | — | — |
| 2026-06-12 | Matthew Lungren | Director | A | — | — |
| 2026-06-12 | Robert Louis Mittl Jr. | Director | A | — | — |
| 2026-06-12 | Henry Lee Cooper | Director | A | — | — |
| 2026-06-12 | GLENN A EISENBERG | Director | A | — | — |
| 2026-06-12 | Molly Joseph | Director | A | — | — |
| 2026-05-21 | BRETT BRODNAX | Director | Buy | — | — |
| 2026-05-18 | Henry Lee Cooper | Director | Buy | — | — |
| 2026-02-27 | James Edward Walker Jr. | Principal Accounting Officer | A | — | — |
| 2026-01-15 | James Anthony Martin | Chief Financial Officer | A | — | — |
| 2025-12-30 | James Edward Walker Jr. | Principal Accounting Officer | A | — | — |
| 2025-12-16 | Julie Szeker | Chief Legal Officer & Corp Sec | MIXED | — | — |
| 2025-12-16 | Molly Joseph | Director | A | — | — |
| 2025-12-16 | Russell Stewart | Chief Medical Officer | A | — | — |
| 2025-12-16 | BRETT BRODNAX | Director | A | — | — |
| 2025-12-16 | Caitlin Zulla | Chief Executive Officer | A | — | — |
| Insider | Role | Shares Held | Value |
|---|---|---|---|
| — | Chief Legal Officer & Corp Sec | 147,263 | — |
| — | Chief Executive Officer | 129,728 | — |
| — | Director | 81,385 | — |
| — | Chief Financial Officer | 54,054 | — |
| — | Director | 49,358 | — |
| — | Director | 46,385 | — |
| — | Director | 19,358 | — |
| — | Director | 19,358 | — |
| — | Director | 19,358 | — |
| — | Director | 19,358 | — |
| — | Principal Accounting Officer | 17,346 | — |
| — | Chief Medical Officer | 4,232 | — |
Form 4 reports a change in beneficial ownership by an officer, director or 10%+ holder, and must be filed within two business days of the transaction — so this is close to real time, unlike the 45-day-lagged 13F institutional data.
Transaction codes matter more than the raw buy/sell count. Code P is an open-market purchase — an insider choosing to buy with their own money, which is the signal most research treats as informative. Code S is a sale, but sales are frequently pre-scheduled under a 10b5-1 plan or cover tax withholding on vesting equity, so a run of sales often says nothing directional. Codes A and M are grants and option exercises rather than open-market decisions.
Full filing history and per-insider positions are on the LMRI quote page; the site-wide leaderboard is on the insider transactions hub.